Market watch: Upcoming market catalysts in Q3 2017,Nature Reviews Drug Discovery

当前位置： X-MOL 学术 › Nat. Rev. Drug. Disc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Market watch: Upcoming market catalysts in Q3 2017
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-06-16 00:00:00 , DOI: 10.1038/nrd.2017.117
Sonny Nghiem

Market catalysts in the third quarter of 2017 include top-line phase III trial results for several therapeutics: patisiran (developed by Alnylam Pharmaceuticals) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN); durvalumab (developed by AstraZeneca) for the first-line treatment of locally advanced or metastatic

中文翻译：

市场观察：2017年第三季度即将到来的市场催化剂

2017年第三季度的市场催化剂包括几种疗法的三线研究的顶级试验结果：patisiran（由Alnylam Pharmaceuticals开发），用于治疗遗传性ATTR淀粉样变性伴多发性神经病（hATTR-PN）；durvalumab（由AstraZeneca开发）用于一线治疗局部晚期或转移性

更新日期：2017-06-29

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>